Alzheimer's disease: current and future therapeutic perspectives

https://doi.org/10.1016/S0278-5846(00)00149-4Get rights and content

Abstract

  • 1.

    A better understanding of the pathophysiology of AD has been made possible through population-based epidemiological studies, human genetic and post-mortem studies, leading to a number of testable hypothesis towards delaying progression.

  • 2.

    A number of disease milestones have been identified as therapeutic targets, such as conversion from MCI to diagnosable dementia.

  • 3.

    Clinicians caring for patients with AD have currently available a number of symptomatic drugs, and will have in the future the ability to predict the risk for asymptomatic individuals to develop AD, and provide advice towards prevention.

References (90)

  • L. Berg et al.

    Mild Senile Dementia of the Alzheimer Type: 2. Longitudinal Assessment

    Ann. Neurol.

    (1988)
  • L. Bracco et al.

    Factors affecting course and survival in Alzheimer's disease

    Arch. Neurol.

    (1994)
  • A. Burns et al.

    Donepezil in the treatment of Alzheimer's disease — Results from a multinational clinical trial

    Dement. Geriat. Cogn. Disord.

    (1999)
  • J. Corey-Bloom et al.

    A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease

    Int. J. Geriat. Psychopharmacol.

    (1998)
  • J.L. Cummings et al.

    The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer's disease

    Neurology

    (1998)
  • J.L. Cummings et al.

    Alzheimer's disease. Etiologies, pathophysiology, cognitive reserve, and treatment opportunities

    Neurology

    (1998)
  • P.A. Cyrus et al.

    The dose-related improvement by metrifonate of the cognitive performance of Alzheimer's disease patients

    Neurology

    (1998)
  • E. Daly et al.

    Predicting conversion to Alzheimer's disease using standardized clinical information

    Arch. Neurol.

    (2000)
  • R. Dejong et al.

    Measurement of quality-of-life changes in patients with Alzheimer's disease

    Clin. Ther.

    (1989)
  • R.S. Doody et al.

    Clinical benefits of donepezil: results from a long-term phase III extension trial

    Neurology

    (1999)
  • G. Emilien et al.

    Prospects for pharmacological intervention in Alzheimer's disease

    Arch. Neurol.

    (2000)
  • M.R. Farlow

    New treatments in Alzheimer Disease and the continued need for placebo-controlled trials

    Arch. Neurol.

    (1998)
  • M.R. Farlow et al.

    Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease

    Neurology

    (1998)
  • M.R. Farlow et al.

    Metrifonate in the symptomatic treatment of Alzheimer's disease: influence of apolipoprotein E genotype

    Neurology

    (1998)
  • H. Feldman et al.

    Benefits of donepezil on global function, behavior, cognition and ADLs in patients with moderate to severe Alzheimer's disease

    Neurology

    (2000)
  • D. Galasko et al.

    The Consortium to establish a Registry for Alzheimer's Diseae (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over three years

    Neurology

    (1995)
  • S. Gauthier

    Clinical trials and therapy

    Current Opinion in Neurology

    (1998)
  • S. Gauthier

    Cholinesterases inhibitors in the treatment of dementia

  • S. Gauthier et al.

    Effects on decline or deterioration

  • I. Gelinas et al.

    The efficacy of metrifonate in enhancing the ability of Alzheimer's disease patients to perform basic and instrumental activities of daily living

    Neurology

    (1998)
  • I. Gelinas et al.

    Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment of Dementia

    A.J.O.T.

    (1999)
  • C. Geula

    Abnormalities of neural circuitry in Alzheimer's disease

    Neurology

    (1998)
  • E. Giacobini

    Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy

  • V.W. Henderson et al.

    Estrogen for Alzheimer's disease in women

    Neurology

    (2000)
  • A. Heyman et al.

    The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease

    Neurology

    (1996)
  • A. Heyman et al.

    Predictors of time to institutionalization of patients with Alzheimer's disease. The CERAD experience, part XVII

    Neurology

    (1997)
  • D.B. Hogan et al.

    Predicting who will develop dementia in a cohort of canadian seniors

    Can. J. Neurol. Sci.

    (2000)
  • M. Kanai et al.

    Longitudinal study of cerebrospinal fluid levels of tau, Abeta1-40, and Abeta1-42(43) in Alzheimer's disease: a study in Japan

    Ann Neurol.

    (1998)
  • J.H.T. Karlawish et al.

    Is the placebo control obsolete in a world after donepezil and vitamin E?

    Arch. Neurol.

    (1998)
  • R. Katzman et al.

    Comparison of annual change of mental status score in four independent studies of patients with Alzheimer's disease

    Ann. Neurol.

    (1988)
  • D.I. Kaufer et al.

    Effects of tacrine on behavioral symptoms in Alzheimer's disease: an open label study

    J. Geriatr. Psychiatry Neurol.

    (1996)
  • D. Knopman et al.

    Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality

    Neurology

    (1996)
  • D. Knopman et al.

    Clinical research designs for emerging treatments to Alzheimer's diseasse: moving beyond placebo-controlled trials

    Arch. Neurol.

    (1998)
  • P. Leber

    Slowing the progression of Alzheimer's disease: methodological issues

    Alz. Dis. Assoc. Disord.

    (1997)
  • U. Lucca et al.

    Rate of progression and prognostic factors in Alzheimer's disease: a prospective study

    J.A.G.S.

    (1993)
  • Cited by (0)

    View full text